Disease-Free (Dfs) And Overall Survival (Os) At 3.4 Years (Yrs) For Neoadjuvant Bevacizumab (Bev) Added To Docetaxel Followed By Fluorouracil, Epirubicin And Cyclophosphamide (D-Fec), For Women With Her2 Negative Early Breast Cancer: The Artemis Trial.

1014Background: ARTemis compared the addition of Bev to neoadjuvant D-FEC in HER2 negative breast cancer. Improved pathological complete response (pCR) with Bev has been reported previously. Methods: We enrolled women ≥ 18 yrs with radiological tumour size u003e 20mm, ± axillary involvement, at 66 centres in the UK. Patients (pts) were randomly assigned to 3 cycles of D (100 mg/m² every [q] 21 days [d]) followed by 3 cycles of F (500mg/m2), E (100mg/m2) and C (500 mg/m²) q 21d (D-FEC), ± 4 cycles Bev (15mg/kg) (Bev+D-FEC). We present the DFS and OS results, analysed by intention-to-treat. pCR is defined by report review; analysis by central pathology review will be available at the time of presentation. Results: Between May’09 and Jan’13, we randomised 800 pts; 401 to D-FEC and 399 to Bev+D-FEC. Median follow-up was 3.4 yrs (IQR 2.5–4.4). 131 deaths and 183 DFS events have occurred. Both OS and DFS were similar across treatments (3-yr OS: Bev+D-FEC 85%, D-FEC 87%; hazard ratio (HR) 0.80 (95%CI 0.57-1.12) p = ...